Gotrade News - European Q1 earnings season delivered three clean beats from very different sectors on Tuesday, as defence group Kongsberg, pharma giant Novo Nordisk, and ingredients leader DSM-Firmenich all topped key forecasts. The common thread is that secular demand drivers, NATO defence buildup, GLP-1 obesity drugs, and premium fragrance plus nutrition, are still pricing through near-term FX and macro headwinds.
Investors got a fresh read on how European industrial and pharmaceutical names are translating order books into reported earnings, with order intake at Kongsberg arguably the standout data point of the day.
Key Takeaways:
- Kongsberg Q1 revenue rose 26% to NOK 9.20 billion but missed the NOK 11.36 billion analyst estimate, while EBIT jumped 55% and order intake more than doubled to NOK 27 billion on a NOK 16 billion counter-drone contract for Poland.
- Novo Nordisk Q1 adjusted operating profit beat expectations as the company leans on Wegovy and a new oral weight-loss pill to defend share against Eli Lilly, with shares climbing 1.08% on the day.
- DSM-Firmenich delivered 4% organic sales growth versus 1.6% expected, EBITDA of EUR 434 million, and kept FY2026 guidance ahead of its SIX Swiss dual listing effective May 21, 2026.
The setup for global investors is straightforward. European primary listings drove the headlines, but the read-through travels through US-listed peers and ADRs that sit on most cross-border brokerage platforms.
For defence, Kongsberg is not directly accessible to many retail US accounts, so the natural comparables are pure-play US defence names like RTX and LMT. Both benefit from the same NATO spending cycle that is filling Kongsberg's order book.
For pharma, NVO is the cleaner expression on US exchanges, while LLY remains the principal competitor in the GLP-1 obesity market.
DSM-Firmenich does not yet have a deep US ADR float, but its Swiss dual listing on May 21 is set to broaden access for international investors who want exposure to fragrance and nutrition.
Kongsberg: Orders Eclipse The Revenue Miss
Kongsberg Gruppen reported Q1 2026 revenue of NOK 9.20 billion, a 26% year-on-year increase that nonetheless came in well below the NOK 11.36 billion analyst consensus. The headline number is the soft spot in the print, and shares slipped 0.98% on the day in a textbook "beat the bottom line, miss the top line" reaction.
According to Investing.com, Q1 EBIT rose 55% to NOK 1.54 billion, lifting the EBIT margin to 16.6% and signalling that Kongsberg is converting its expanded backlog into stronger profitability faster than the top line would suggest.
The number that matters most for the multi-quarter thesis is order intake. Kongsberg booked NOK 27 billion of new orders in Q1, more than double the prior-year period. The single largest contributor was a NOK 16 billion contract to supply counter-unmanned aerial systems to Poland.
Demand for weapon stations and counter-drone systems remains elevated as European NATO members rebuild stockpiles. Kongsberg guided for full-year 2026 revenue to exceed 2025 levels and flagged record-high demand across the product portfolio.
The investor takeaway is that the revenue miss is a timing issue against a backlog that has effectively pre-sold future quarters. Defence peers like RTX and LMT, which sell into the same NATO replenishment cycle through different product mixes, see a clean read-through.
Novo Nordisk And DSM-Firmenich: Pharma And Ingredients Beat
Novo Nordisk reported Q1 2026 adjusted operating profit ahead of consensus, with the company leaning on continued strong Wegovy demand in obesity. Management is also pinning growth on a new oral weight-loss pill that competes head-on with Eli Lilly's pipeline.
Per Investing.com's report on Novo Nordisk, investors are now demanding evidence that rising volumes can absorb the ongoing obesity drug price war, particularly in the United States. NVO shares closed up 1.08% on the print.
For exposure on US-listed venues, NVO trades as a sponsored ADR on the NYSE and is one of the most liquid pharmaceutical names on cross-border brokerage platforms. LLY remains the principal competitor and the natural pair trade for any view on GLP-1 market share.
DSM-Firmenich beat with 4% organic sales growth versus 1.6% expected, total Q1 sales of EUR 2,276 million, and adjusted EBITDA of EUR 434 million, slightly ahead of the EUR 428 million estimate. Volume rose 4%, partly offset by a 6% negative FX impact, which is the same currency drag that has compressed earnings across European multinationals.
Perfumery and Beauty was the standout segment with EUR 967 million in sales and 8% organic growth, including double-digit like-for-like growth in fine fragrance. Health, Nutrition and Care delivered EUR 497 million in sales and 4% organic growth, with adjusted EBITDA of EUR 96 million coming in 6% above estimate.
Asia and Latin America remained soft, and management noted some March order advancement amid customer uncertainty. FY2026 guidance was maintained at 2 to 4% organic sales growth and an adjusted EBITDA margin around 20%, with the SIX Swiss dual listing scheduled for May 21, 2026.
Across all three names, the pattern is consistent. Order books are growing faster than reported revenue, secular demand is intact, and currency remains the cleanest near-term drag. For brokerage clients with access to US tickers, RTX, LMT, NVO, and LLY are the most direct vehicles to express the European earnings read-through.
Sources:
